Nicox, and Glaukos ink exclusive NCX 1728 research and global licensing option agreement: Sophia Antipolis, France Tuesday, September 24, 2024, 17:00 Hrs [IST] Nicox SA, an intern ...

The company believes these combinations create a broader approach to treating neurodegenerative diseases ・Preclinical studies have demonstrated these combinations significant ...

The benefits do not stop there. Recent studies suggest GLP-1 drugs may also reduce the risk of heart disease, kidney disease and stroke, and even possibly protect the brain from AD by reducing ...

Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and ...

Annovis is at the forefront, testing buntanetap in pivotal clinical trials as a therapy for Alzheimer's and Parkinson's diseases (PD). Company has filed three new patents protecting combinations of ...

Alzheimer's disease (AD) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received ...

Petragen Inc. has described ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer, gingivitis, musculoskeletal and ...

Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative ...

According to researchers, apremilast is the only oral phosphodiesterase 4 inhibitor that significantly improves symptoms of ...

Prostaglandin analogues and phosphodiesterase inhibitors, either alone or as add-on therapy, are effective treatments for vitiligo repigmentation.

The company has also reported positive data for PDE4 inhibitor, orismilast, in psoriasis, hidradenitis suppurativa, and ...